Cryptdin-2: A novel therapeutic agent for experimental Salmonella Typhimurium infection

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 5, 2010, Pages 991-994

  Preet, Simran ^a   Verma, Indu ^b   Rishi, Praveen ^a  

^a PANJAB UNIVERSITY   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Antimicrobial peptides; Salmonella typhimurium; Therapeutic efficacy

Indexed keywords

ANTIINFECTIVE AGENT; CRYPTDIN 2; UNCLASSIFIED DRUG; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; INTESTINE; LIVER; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; SPLEEN; ANIMAL; BACTERIAL COUNT; BAGG ALBINO MOUSE; DRUG EFFECT; MACROPHAGE; MICROBIAL VIABILITY; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; FEMALE; INTESTINES; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MICROBIAL VIABILITY; PROTEINS; SALMONELLA INFECTIONS; SALMONELLA TYPHIMURIUM; SPLEEN;

EID: 77953726931     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq066     Document Type: Article

References (10)

1. Birosova L, Mikulasova M. Development of triclosan and antibiotic resistance in Salmonella enterica serovar Typhimurium. J Med Microbiol 2009; 58: 436-41.
2. Ricci V, Piddock LJ. Ciprofloxacin selects for multidrug resistance in Salmonella enterica serovar Typhimurium mediated by at least two different pathways. J Antimicrob Chemother 2009; 63: 909-16.
3. Sharma S, Verma I, Khuller GK. Therapeutic potential of human neutrophil peptide-1 against experimental tuberculosis. Antimicrob Agents Chemother 2001; 45: 639-40.
4. Doss M, White MR, Tecle T et al. Interactions of α-, β-, and θ-defensins with influenza A virus and surfactant protein D. J Immunol 2009; 182: 7878-87.
5. Ouellette AJ, Hsieh MM, Nosek MT et al. Mouse Paneth cell defensins: primary structures and antibacterial activities of numerous cryptdin isoforms. Infect Immun 1994; 62: 5040-7.
6. Rishi P, Mavi S, Bharrhan S et al. Protective efficacy of probiotic alone or in conjunction with a prebiotic in Salmonella-induced liver damage. FEMS Microbiol Ecol 2009; 69: 222-30.
7. Piddock LJV, Ricci V, McLaren I et al. Role of mutation in the gyrA and parC genes of nalidixic-acid-resistant salmonella serotypes isolated from animals in the United Kingdom. J Antimicrob Chemother 1998; 41: 635-41.
8. Ericksen B, Wu Z, LuWet al. Antibacterial activity and specificity of the six human α-defensins. Antimicrob Agents Chemother 2005: 49: 269-75.
9. Rosenberger CM, Gallo RL, Finlay BB. Interplay between antibacterial effectors: a macrophage antimicrobial peptide impairs intracellular Salmonella replication. Proc Natl Acad Sci USA 2004; 101: 2422-7.
10. Kuckelhaus S, Leite JRSA, Neves MP et al. Toxicity evaluation to mice of phylloseptin-1, an antimicrobial peptide from the skin secretion of Phyllomedusa hypochondrialis (Amphibia). Int J Peptide Res Ther 2007; 13: 423-9.